International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 141-147
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Upregulation of Telomerase Activity by HER-2/neu and Its Significance in Breast Cancer
Karuvaje THRIVENI1, Rani JAMES1, Lakshmi KRISHNAMOORTHY1, Vijayalakxmi DESHMANE2, Padmanabhan BAPSY3, Girija RAMASWAMY1
1Kidwai Memorial Institute of Oncology, Department of Biochemistry, Bangalore, INDIA
2Kidwai Memorial Institute of Oncology, Department of Surgical Oncology, Bangalore, INDIA
3Kidwai Memorial Institute of Oncology, Department of Medical Oncology, Bangalore, INDIA
Keywords: HER-2/neu, Telomerase activity, Prognostic factors, Signal transduction
The protooncogene- Human epidermal growth factor receptor (HER-2/neu) is overexpressed in 20-30% of breast cancer patients. Telomerase activity provides the molecular basis for unlimited proliferate potential of the tumor. HER-2/neu and hTERT (component of telomerase) are two antigens that are particularly appealing for a broad spectrum immunotherapy. The objective of the present study was to evaluate the association between HER-2/neu status (serum and tissue) and telomerase activity with other prognostic factors in breast cancer patients.
Serum HER-2/neu levels, CEA and CA15-3 were analysed in 268 patients with breast cancer and 175 age-matched healthy controls by enzyme linked immunosorbent assay (ELISA). Immuno histochemical (IHC) method was used for tissue HER- 2/neu expression in 75 samples. Telomerase activity was measured by polymerase chain reaction enzyme immuno assay (PCR-EIA) method.
Serum HER-2/neu levels were elevated in 27.2% of patients and associated with age >40 years, premenopausal group, node positive, stage and grade of disease, but not with hormone receptor status. Telomerase activity was significantly increased in 89% of the cases. Significant correlation existed between levels of serum HER-2/neu and telomerase activity (p< 0.001, r =0.49) in breast cancer patients.
Levels of serum HER-2/neu correlated with telomerase activity in the premenopausal group age >40 years and also in the early stage of the disease. Combination of these two markers may have better predictive value in the management of breast cancer.
Karuvaje THRIVENI1, Rani JAMES1, Lakshmi KRISHNAMOORTHY1, Vijayalakxmi DESHMANE2, Padmanabhan BAPSY3, Girija RAMASWAMY1
1Kidwai Memorial Institute of Oncology, Department of Biochemistry, Bangalore, INDIA
2Kidwai Memorial Institute of Oncology, Department of Surgical Oncology, Bangalore, INDIA
3Kidwai Memorial Institute of Oncology, Department of Medical Oncology, Bangalore, INDIA
Keywords: HER-2/neu, Telomerase activity, Prognostic factors, Signal transduction
The protooncogene- Human epidermal growth factor receptor (HER-2/neu) is overexpressed in 20-30% of breast cancer patients. Telomerase activity provides the molecular basis for unlimited proliferate potential of the tumor. HER-2/neu and hTERT (component of telomerase) are two antigens that are particularly appealing for a broad spectrum immunotherapy. The objective of the present study was to evaluate the association between HER-2/neu status (serum and tissue) and telomerase activity with other prognostic factors in breast cancer patients.
Serum HER-2/neu levels, CEA and CA15-3 were analysed in 268 patients with breast cancer and 175 age-matched healthy controls by enzyme linked immunosorbent assay (ELISA). Immuno histochemical (IHC) method was used for tissue HER- 2/neu expression in 75 samples. Telomerase activity was measured by polymerase chain reaction enzyme immuno assay (PCR-EIA) method.
Serum HER-2/neu levels were elevated in 27.2% of patients and associated with age >40 years, premenopausal group, node positive, stage and grade of disease, but not with hormone receptor status. Telomerase activity was significantly increased in 89% of the cases. Significant correlation existed between levels of serum HER-2/neu and telomerase activity (p< 0.001, r =0.49) in breast cancer patients.
Levels of serum HER-2/neu correlated with telomerase activity in the premenopausal group age >40 years and also in the early stage of the disease. Combination of these two markers may have better predictive value in the management of breast cancer.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |